Influenza is a significant cause of morbidity and mortality in both children and adults and is associated with hospitalization in children aged <5 years1). Neuraminidase (NA) inhibitors (NAIs), such as oseltamivir, zanamivir, and laninamivir, have become primary treatment options for patients with influenza virus infection.
Among these NAIs, the dry syrup formulation of oseltamivir is the one mostly prescribed for children. Since the 2009-2010 influenza season and after the seasonal influenza virus H1N1 was replaced by the pandemic A H1N1 in 2009 (H1N1 pdm09), a few oseltamivir-resistant H1N1 pdm09 viruses have been isolated. For the 2009-2010 influenza season, oseltamivir-resistant H1N1 pdm09 viruses represented <1% of viruses detected in the United States, with most cases being isolated from patients who received oseltamivir2,3). However, in December 2013, oseltamivir-resistant H1N1 pdm09 with an H275Y substitution in NA (H1N1 pdm09 H275Y) was identified in Japanese patients who had not been exposed to oseltamivir4,5). This indicated that the variant would spread globally and that all H1N1 pdm09 cases would be resistant to oseltamivir in the near future based on seasonal H1N1 trends until the 2008-2009 influenza season5). Furthermore, an H3N2 virus subtype with an E119V (H3N2 E119V) and R292K substitution (H3N2 R292K) in NA has been identified, with reduced susceptibility to oseltamivir. The susceptibility of the influenza virus to NAIs is demonstrated by the 50% inhibitory concentration (IC50) for NA activity; the methods for measuring IC50 and the definition of susceptibility have been standardized by the World Health Organization6). However, because the current NA inhibition assay requires virus isolation following cell culture, it cannot provide rapid results to clinicians. Although the variant population was responsible for the apparent increase in IC50 values7), there was a difference in NAI-resistant variant populations between clinical specimens and isolated viruses because of wild-type (WT) strain selection during cell culture8-10). Therefore, developing a method for rapid quantitative detection of WT and variant strains using clinical specimens is necessary to predict the IC50 values in clinical settings.
Recently, quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) using specific probes composed of locked nucleic acids (LNA/qRT-PCR) to quantitatively detect major H1N1 pdm09 and H3N2 oseltamivir-resistant variants was demonstrated9,11,12). This PCR method allows for rapid viral susceptibility prediction and is expected to be useful in clinical practice. Therefore, in our study, we investigated whether this novel PCR method can be used to predict the susceptibility of viruses in obtained clinical specimens.